Helix BioPharma Corp., a clinical-stage oncology company, has announced the appointment of Markus Loeffler, MD, MBA, as Chief Medical Officer (CMO), effective immediately. This leadership addition comes as the company prepares to enter a more execution-focused phase, with several programs approaching key regulatory and clinical milestones. Dr. Loeffler will lead the strategy and execution of Helix's clinical programs, including the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab for first-line non-small cell lung cancer (NSCLC) and the advancement of LEUMUNA™ toward clinical development for leukemia relapse following allogeneic stem cell transplantation.
The appointment is a critical step for Helix as it seeks to translate its innovative science into late-stage clinical development. Thomas Mehrling, MD, PhD, CEO of Helix, highlighted Dr. Loeffler's proven ability to bridge scientific innovation and clinical execution. "I've had the privilege of working with Markus before, and I have seen firsthand his ability to translate innovative science into well-executed clinical development programs," said Mehrling. "He is an outstanding clinical development leader with a strong track record of advancing innovative oncology therapies through the development pathway. His expertise will be instrumental as we advance L-DOS47 into its next stage of clinical development and prepare LEUMUNA to enter the clinic."
Dr. Loeffler brings over three decades of leadership in oncology drug development, with extensive experience advancing small molecules, biologics, antibody-drug conjugates (ADCs), radiopharmaceuticals, and immunotherapies from early clinical stages through Phase III and regulatory approval. He has held senior clinical development and CMO roles at prominent companies including Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals, and SK Life Science. Notably, he led the pivotal Phase III clinical program for Lutathera®, which received approval for certain gastroenteropancreatic neuroendocrine tumors.
In his new role, Dr. Loeffler expressed enthusiasm about the company's pipeline, which combines strong scientific foundations with clear clinical opportunities. "I'm excited to join Helix at such an important stage in its evolution," he said. "The Company's pipeline combines strong scientific foundations with clear clinical development opportunities. I am particularly enthused by the opportunity to advance L-DOS47 in combination with checkpoint inhibition and to bring LEUMUNA toward its first clinical evaluation. I look forward to working alongside the team to translate these programs into meaningful new treatment options for patients with difficult-to-treat cancers."
Helix BioPharma is focused on developing therapies for underserved patient populations with difficult-to-treat cancers. Its pipeline is led by L-DOS47, an antibody-enzyme conjugate being developed as a combination therapy for NSCLC. Additional candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. The company's shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCF), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information, visit https://www.helixbiopharma.com/.
This appointment is pivotal as Helix approaches significant milestones. The planned Phase Ib/II trial of L-DOS47 in combination with pembrolizumab could position the company to address a substantial unmet need in NSCLC. Meanwhile, LEUMUNA's advancement into the clinic represents a novel approach to treating leukemia relapse post-transplant. Dr. Loeffler's expertise in guiding therapies through regulatory approval will be invaluable in navigating the complexities of clinical development and bringing these potential treatments to patients.
